This article was originally published in The Rose Sheet
You may also be interested in...
The Senate Appropriations Committee gives FDA a boost for fiscal 2012 that likely will stick, thanks to the recent debt ceiling compromise.
Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.
The US Food and Drug Administration and the Veterans Health Administration are partnering to create tools that can help novel technology reach patients more quickly and easily.